A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503468-17-00

Acronym

64407564MMY1002

Enrollment

111

Registered

2024-06-07

Start date

2020-03-02

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026